Tuberculosis in renal transplant recipients

Area of Science:

• Nephrology
• Infectious Diseases
• Transplantation Immunology

Background:

• Infective complications, particularly tuberculosis (TB), are frequent post-renal transplantation.
• Reactivation of latent TB is the primary infection route in these patients.
• Immunosuppressive therapy significantly increases the risk of TB reactivation.

Purpose of the Study:

• To review the epidemiology, risk factors, clinical presentation, diagnosis, and management of tuberculosis in renal transplant recipients.
• To highlight the impact of different immunosuppressive agents on TB onset.
• To provide guidance on drug selection and treatment duration for TB in this vulnerable population.

Main Methods:

• Literature review focusing on TB in renal transplant patients.
• Analysis of factors influencing TB reactivation and onset.
• Evaluation of diagnostic techniques, including serological methods like Interferon-gamma release assays.
• Review of treatment protocols and drug interactions.

Main Results:

• Cyclosporine-based immunosuppression accelerates TB onset compared to azathioprine/prednisolone.
• The lungs are the most common site of TB infection, with pyrexia of unknown origin being a frequent presentation.
• Interferon-alpha production shows promise as a diagnostic marker.
• Rifampicin must be avoided due to cytochrome-P450 induction, reducing immunosuppressant efficacy.

Conclusions:

• Tuberculosis poses a significant threat to renal transplant recipients, necessitating vigilant monitoring.
• Optimized diagnostic strategies and careful drug management, including avoiding rifampicin, are essential.
• Extended treatment durations (18 months) with secondary prophylaxis are recommended, with close monitoring for adverse effects and drug resistance.